Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00124956Phase 1Withdrawn

Doxorubicin Pharmacokinetic (PK) Study

Role: collaborator

NCT00277251Phase 2Completed

Alendronate Osteoporosis Study

Role: collaborator

NCT01713738Phase 1Completed

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Role: collaborator

NCT00120159Unknown

Necrotizing Enterocolitis (NEC) Surgical Database

Role: collaborator

NCT00209482Phase 2Unknown

Glaser Obesity Study

Role: lead

NCT00209469Phase 2Unknown

Network Osteoporosis Study

Role: lead

All 6 trials loaded